Abstract

Background Diabetes can be detected at the primary health-care level, and effective treatments lower the risk of complications. There are insufficient data on the coverage of treatment for diabetes and how it has changed. Weestimated trends from 1990 to 2022 in diabetes prevalence and treatment for 200 countries and territories. Methods We used data from 1108 population-representative studies with 141 million participants aged 18 years and older with measurements of fasting glucose and glycated haemoglobin (HbA1c), and information on diabetes treatment. We defined diabetes as having a fasting plasma glucose (FPG) of 7·0 mmol/L or higher, having an HbA1c of 6·5% or higher, or taking medication for diabetes. We defined diabetes treatment as the proportion of people with diabetes who were taking medication for diabetes. We analysed the data in a Bayesian hierarchical meta-regression model to estimate diabetes prevalence and treatment.

Findings In 2022, an estimated 828 million (95% credible interval [CrI] 757–908) adults (those aged 18 years and older) had diabetes, an increase of 630 million (554–713) from 1990. From 1990 to 2022, the age-standardised prevalence of diabetes increased in 131 countries for women and in 155 countries for men with a posterior probability of more than 0·80. The largest increases were in low-income and middle-income countries in southeast Asia (eg, Malaysia), south Asia (eg, Pakistan), the Middle East and north Africa (eg, Egypt), and Latin America and the Caribbean (eg, Jamaica, Trinidad and Tobago, and Costa Rica). Age-standardised prevalence neither increased nor decreased with a posterior probability of more than 0·80 in some countries in western and central Europe, sub-Saharan Africa, east Asia and the Pacific, Canada, and some Pacific island nations where prevalence was already high in 1990; it decreased with a posterior probability of more than 0·80 in women in Japan, Spain, and France, and in men in Nauru. The lowest prevalence in the world in 2022 was in western Europe and east Africa for both sexes, and in Japan and Canada for women, and the highest prevalence in the world in 2022 was in countries in Polynesia and Micronesia, some countries in the Caribbean and the Middle East and north Africa, as well as Pakistan and Malaysia. In 2022, 445 million (95% CrI 401–496) adults aged 30 years or older with diabetes did not receive treatment (59% of adults aged 30 years or older with diabetes), 3·5 times the number in 1990. From 1990 to 2022, diabetes treatment coverage increased in 118 countries for women and 98 countries for men with a posterior probability of more than 0·80. The largest improvement in treatment coverage was in some countries from central and western Europe and Latin America (Mexico, Colombia, Chile, and Costa Rica), Canada, South Korea, Russia, Seychelles, and Jordan. There was no increase in treatment coverage in most countries in sub-Saharan Africa; the Caribbean; Pacific island nations; and south, southeast, and central Asia. In 2022, age-standardised treatment coverage was lowest in countries in sub-Saharan Africa and south Asia, and treatment coverage was less than 10% in some African countries. Treatment coverage was 55% or higher in South Korea, many high-income western countries, and some countries in central and eastern Europe (eg, Poland, Czechia, and Russia), Latin America (eg, Costa Rica, Chile, and Mexico), and the Middle East and north Africa (eg, Jordan, Qatar, and Kuwait).

Interpretation In most countries, especially in low-income and middle-income countries, diabetes treatment has not increased at all or has not increased sufficiently in comparison with the rise in prevalence. The burden of diabetes and untreated diabetes is increasingly borne by low-income and middle-income countries. The expansion of health insurance and primary health care should be accompanied with diabetes programmes that realign and resource health services to enhance the early detection and effective treatment of diabetes.

1. ElSayed NA, Aleppo G, Bannuru RR et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024; 47:S158-S178.
2. Adler AI, Coleman, RL, Leal, J et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91) Lancet. 2024; 404:145-155.
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024; 403:1027-1050
4. Babar, ZU, Ramzan, S, El-Dahiyat, F et al. The availability, pricing, and affordability of essential diabetes medicines in 17 low-, middle-, and high-income countries. Front Pharmacol. 2019; 10:1375.
5. Chow, CK, Ramasundarahettige C, Hu W et al. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Lancet Diabetes Endocrinol. 2018; 6:798-808.
6. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41:255-323.
7. CENETEC. Prevención, diagnóstico, tratamiento inicial, metas de control ambulatorio y referencia oportuna de la diabetes mellitus tipo 2 en el primer nivel de atención. Guía de Evidencias y Recomendaciones: Guía de Práctica Clínica https://www.cenetec-difusion.com/ CMGPC/GPC-SS-093-19/ER.pdf Date: 2019. Date ac- cessed: June 5, 2024.
8. SEMDSA. Type 2 Diabetes Guidelines Expert Committee. SEMDSA 2017 guidelines for the management of type 2 diabetes mellitus. J Endocrinol Metab Diabetes South Africa. 2017; 22:S1-196.
9. Makkar BM, Kumar CV, Saboo B et al. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022. Int J Diabetes Dev Ctries. 2022; 42:1-143.
10. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398:957-980.
11. Ikeda N, Nishi N, Noda H, et al. Trends in prevalence and management of diabetes and related vascular risks in Japanese adults: Japan National Health and Nutrition Surveys 2003-2012. Diabetes Res Clin Pract. 2017; 127: 115-122.
12. López Rey MJ, Docampo García M. Change over time in prevalence of diabetes mellitus (DM) in Spain (1999-2014). Endocrinol Diabetes Nutr (Engl Ed). 2018; 65:515-523.
13. Fuentes S, Mandereau-Bruno L, Regnault N et al. Is the type 2 diabetes epidemic plateauing in France? A nationwide population-based study. Diabetes Metab. 2020; 46:472-479.
14. Basit A, Fawwad A, Qureshi H et al. Prevalence of diabetes, pre-diabetes and associated risk factors: second National Diabetes Survey of Pakistan (NDSP), 2016–2017. BMJ Open. 2018; 8:e020961.
15. National Institutes of Health, Ministry of Health Malaysia. National Health and Morbidity Survey 2019, techni- cal report—volume I, NCDs—non-communicable dis- eases: risk factors and other health problems. https:// iptk.moh.gov.my/images/technical_report/2020/Re- port_NHMS2019-NCD.pdf Date accessed: June 7, 2024.
16. Islam MT, Bruce M, Alam K. Cascade of diabetes care in Bangladesh, Bhutan and Nepal: identifying gaps in the screening, diagnosis, treatment and control continuum. Sci Rep. 2023; 13:10285.
17. Chen KuCH, Chen-Sandi D. The health system in Costa Rica: focus on the management of diabetes mellitus. Cureus. 2023; 15:e40084.
18. Saadeh R, Alsmadi H, Batieha A et al. Quality of care for type 2 diabetes in Jordan: a national study. Med Int (Lond). 2023; 3:27.
19. Sun H, Saeedi P, Karuranga S et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183:109119.
20. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023; 402:203-234.
21. ElSayed NA, Aleppo, Bannuru RR et al. 2. Diagnosis and classification of diabetes: standards of care in diabetes—2024. Diabetes Care. 2024; 47:S20-S42.
22. WHO. Classification of diabetes mellitus 2019. https://iris. who.int/bitstream/handle/10665/325182/9789241515702- eng.pdf Date accessed: May 31, 2024.
23. International Diabetes Federation. IDF clinical practice recommendations for managing type 2 diabetes in pri- mary care. https://idf.org/media/uploads/2023/05/attachments-63.pdf Date: 2017. Date accessed: May 31, 2024.
24. Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Zhonghua Neifenmi Daixie Zazhi. 2021; 37:311-398.
25. NCD Risk Factor Collaboration (NCD-RisC). Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A1c. Nat Med. 2023; 29:2885-2901.
26. Anjana RM, Unnikrishnan R, Deepa M et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-IN- DIAB-17). Lancet Diabetes Endocrinol. 2023; 11:474-489.
27. Gujral UP, Prabhakaran D, Pradeepa R et al. Isolated HbA1c identifies a different subgroup of individuals with type 2 diabetes compared to fasting or post-challenge glu- cose in Asian Indians: the CARRS and MASALA studies. Diabetes Res Clin Pract. 2019; 153:93-102.
28. Wang L, Li X, Wang Z et al. Trends in prevalence of diabetes and control of risk factors in diabetes among US adults, 1999–2018. JAMA. 2021; 326:1-13.
29. Menke, A ∙ Casagrande, S ∙ Geiss, L ∙ et al. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA. 2015; 314:1021-1029.
30. Basto-Abreu AC, Lopez-Olmedo N, Rojas-Martinez R et al. Prevalence of diabetes and glycemic control in Mexico: national results from 2018 and 2020. Salud Pu- blica Mex. 2021; 63:725-733.
31. Jeon JY, Ko SH, Kwon HS et al. Prevalence of diabetes and prediabetes according to fasting plasma glucose and HbA1c. Diabetes Metab J. 2013; 37:349-357.
32. Rosella LC, Lebenbaum M, Fitzpatrick T et al. Prevalence of prediabetes and undiagnosed diabetes in Canada (2007–2011) according to fasting plasma glucose and HbA1c screening criteria. Diabetes Care. 2015; 38: 1299-1305.
33. Rannan-Eliya RP, Wijemunige N, Perera P et al. Prevalence of diabetes and pre-diabetes in Sri Lanka: a new global hotspot-estimates from the Sri Lanka Health and Ageing Survey 2018/2019. BMJ Open Diabetes Res Care. 2023; 11:e003160.
34. Nazir A, Papita R, Anbalagan VP et al. Prevalence of diabetes in Asian Indians based on glycated hemoglobin and fasting and 2-H post-load (75-g) plasma glucose (CURES-120). Diabetes Technol Ther. 2012; 14:665-668.
35. Pauli A, de Mestral C, Marques-Vidal P. Trends in diabetes prevalence, awareness, treatment, and control in French-speaking Switzerland. Sci Rep. 2024; 14:4839.
36. Lilja M, Eliasson M, Eriksson M et al. A rightward shift of the distribution of fasting and post-load glucose in northern Sweden between 1990 and 2009 and its predictors. Data from the Northern Sweden MONICA study. Diabet Med. 2013; 30:1054-1062.
37. Chang HY, Hsu CC, Pan WH et al. Gender differences in trends in diabetes prevalence from 1993 to 2008 in Taiwan. Diabetes Res Clin Pract. 2010; 90:358-364.
38. Heidemann C, Du Y, Paprott R et al. Temporal changes in the prevalence of diagnosed diabetes, undiagnosed diabetes and prediabetes: findings from the German Health Interview and Examination Surveys in 1997–1999 and 2008–2011. Diabet Med. 2016; 33:1406-1414.
39. Magliano DJ, Chen L, Islam RM et al. Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings. Lancet Diabetes Endocrinol. 2021; 9:203-211.
40. Tuomilehto J. The emerging global epidemic of type 1 diabetes. Curr Diab Rep. 2013; 13:795-804.
41. Ley SH, Hamdy O, Mohan V et al. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet. 2014; 383:1999-2007.
42. Chen M, Sun Q, Giovannucci E et al. Dairy consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. BMC Med. 2014; 12:215.
43. Hu Y, Ding M, Sampson L et al. Intake of whole grain foods and risk of type 2 diabetes: results from three prospective cohort studies. BMJ. 2020; 370:m2206.
44. Li M, Fan Y, Zhang X et al. Fruit and vegetable intake and risk of type 2 diabetes mellitus: meta-analysis of prospective cohort studies. BMJ Open. 2014; 4:e005497.
45. Imamura F, O’Connor L, Ye Z et al. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ. 2015; 351:h3576.
46. Bhavadharini B, Mohan V, Dehghan M et al. White rice intake and incident diabetes: a study of 132,373 participants in 21 countries. Diabetes Care. 2020; 43:2643-2650.
47. Mohan V, Radhika G, Sathya RM et al. Dietary carbohydrates, glycaemic load, food groups and newly detected type 2 diabetes among urban Asian Indian population in Chennai, India (Chennai Urban Rural Epidemiology Study 59). Br J Nutr. 2009; 102:1498-1506.
48. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3:866-875.
49. Saaristo T, Moilanen L, Korpi-Hyövälti E et al. Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). Diabetes Care. 2010; 33:2146-2151.
50. Ramachandran A, Snehalatha C, Mary S et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006; 49:289-297.
51. Chakkalakal RJ, Galaviz KI, Thirunavukkarasu S et al. Test and treat for prediabetes: a review of the health effects of prediabetes and the role of screening and prevention. Annu Rev Public Health. 2024; 45:151-167.
52. Echouffo-Tcheugui JB, Perreault LJiL et al. Diagnosis and management of prediabetes: a review. JAMA. 2023; 329:1206-1216.
53. Haw JS, Galaviz KI, Straus AN et al. Long-term sustain-ability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2017; 177:1808-1817.
54. Galaviz KI, Weber MB, Suvada K et al. Interventions for reversing prediabetes: a systematic review and meta- analysis. Am J Prev Med. 2022; 62:614-625.
55. Jonas DE, Crotty K, Yun JDY et al. Screening for prediabetes and type 2 diabetes: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021; 326:744-760.
56. Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020; 16:377-390.
57. Bhargava SK, Sachdev HS, Fall CH et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med. 2004; 350:865-875.
58. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348:383-393.
59. Fox CS, Golden SH, Anderson C et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a sci- entific statement from the American Heart Association and the American Diabetes Association. Circulation. 2015; 132:691-718.
60. Wu H, Yang A, Lau ESH et al. 1-year weight change after diabetes diagnosis and long-term incidence and sustain- ability of remission of type 2 diabetes in real-world set- tings in Hong Kong: an observational cohort study. PLoS Med. 2024; 21:e1004327.
61. Ali MK, Singh K, Kondal D et al. Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: post hoc analyses of the CARRS randomized clinical trial. PLoS Med. 2024; 21:e1004335.
62. Valabhji J, Gorton T, Barron E et al. Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation. Lancet Diabetes Endocrinol. 2024; 12:653-663.
63. Kruk ME, Nigenda G, Knaul FM. Redesigning primary care to tackle the global epidemic of noncommunicable disease. Am J Public Health. 2015; 105:431-437.
64. Farzadfar F, Murray CJ, Gakidou E et al. Effectiveness of diabetes and hypertension management by rural primary health-care workers (Behvarz workers) in Iran: a nationally representative observational study. Lancet. 2012; 379:47-54.
65. India Tuberculosis-Diabetes Study Group. Screening of patients with tuberculosis for diabetes mellitus in India. Trop Med Int Health. 2013; 18:636-645.
66. Lekoubou A, Awah P, Fezeu L et al. Hypertension, diabetes mellitus and task shifting in their management in sub-Saharan Africa. Int J Environ Res Public Health. 2010; 7:353-363.
67. Willis A, Rivers P, Gray LJ et al. The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting PLoS One. 2014; 9:e91157.
68. Jindal D, Sharma H, Gupta Y et al. Improving care for hyperten- sion and diabetes in india by addition of clinical decision support system and task shifting in the national NCD program: I-TREC model of care. BMC Health Serv Res. 2022; 22:688.
69. Toscano CM, Duncan BB, Mengue SS et al. Initial impact and cost of a nationwide population screening campaign for diabetes in Brazil: a follow up study. BMC Health Serv Res. 2008; 8:189.
70. Kivuyo S, Birungi J, Okebe J et al. Integrated manage- ment of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial. Lancet. 2023; 402:1241-1250.
71. Bali V, Yermilov I, Koyama A et al. Secondary prevention of diabetes through workplace health screening. Occup Med (Lond). 2018; 68:610-616.
72. Finnish Diabetes Association Diabetes Centre. Development Programme for the Prevention and Care of Diabetes in Finland 2000–2010. Tampere: Finnish Diabetes Association, 2001 https://www.diabetes.fi/files/200/Development_Programme_for_the_Prevention_and_Care_of_ Diabetes_2000_2010_pdf_910_kB.pdf Date accessed: August 19, 2024.
73. Ewen M, Joosse HJ, Beran D et al. Insulin prices, avail- ability and affordability in 13 low-income and middle-income countries. BMJ Glob Health. 2019; 4:e001410.
74. Shah S, Singh K, Ali MK et al. Improving diabetes care: multi-component cardiovascular disease risk reduction strategies for people with diabetes in South Asia — the CARRS multi-center translation trial. Diabetes Res Clin Pract. 2012; 98:285-294.